338840 — Y Biologics Balance Sheet
0.000.00%
- KR₩108bn
- KR₩98bn
- KR₩6bn
Annual balance sheet for Y Biologics, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|
Period Length: | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | ARS | Annual Audited Accounts |
Standards: | — | — | IFRS | IFRS |
Status: | Final | Final | Final | Final |
Cash and Equivalents | ||||
Short Term Investments | ||||
Cash and Short Term Investments | 16,948 | 12,983 | 20,898 | 12,204 |
Net Total Accounts Receivable | ||||
Net Total Receivables | 2,083 | 895 | 639 | 194 |
Prepaid Expenses | ||||
Total Other Current Assets | ||||
Total Current Assets | 19,845 | 18,034 | 21,763 | 12,471 |
Gross Property, Plant And Equipment | ||||
Accumulated Depreciation | ||||
Net Property, Plant And Equipment | 16,824 | 10,801 | 8,009 | 7,407 |
Net Intangible Assets | ||||
Long Term Investments | ||||
Other Long Term Assets | ||||
Total Assets | 38,245 | 29,323 | 30,294 | 21,727 |
Accounts Payable | ||||
Payable / Accrued | ||||
Accrued Expenses | ||||
Notes Payable / Short Term Debt | ||||
Current Portion of Long Term Debt / Capital Leases | ||||
Total Other Current Liabilities | ||||
Total Current Liabilities | 6,209 | 16,195 | 5,508 | 2,444 |
Long Term Debt | ||||
Capital Lease Obligations | ||||
Total Long Term Debt | ||||
Total Debt | ||||
Total Other Liabilities | ||||
Total Liabilities | 9,803 | 17,029 | 6,886 | 3,371 |
Common Stock | ||||
Additional Paid In Capital | ||||
Retained Earnings (Accumulated Deficit) | ||||
ESOP Debt Guarantee | ||||
Other Equity | ||||
Total Equity | 28,441 | 12,293 | 23,408 | 18,356 |
Total Liabilities & Shareholders' Equity | 38,245 | 29,323 | 30,294 | 21,727 |
Total Common Shares Outstanding | ||||
Total Preferred Shares Outstanding |